In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeria Pharmaceutical Co. Ltd.

www.zeria.co.jp

Latest From Zeria Pharmaceutical Co. Ltd.

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Deals Business Strategies

Going Solo Suits Vifor And Its Hopes For Two Blockbusters

Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.

Sales & Earnings Renal

Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns

Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.

Japan Reimbursement

PIPELINE WATCH: A Strong Analgesic Meets Primary Endpoint, But An RNAi Therapeutic Disappoints

Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Dermatology
  • Inflammation
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Zeria Pharmaceutical Co. Ltd.
  • Senior Management
  • Sachiaki Ibe, CEO
    Mitsuhiro Ibe, Pres. & COO
  • Contact Info
  • Zeria Pharmaceutical Co. Ltd.
    Phone: (81) 3 3663 2351
    10-11 Nihonbashi Kobuna-cho
    Chuo-Ku
    Tokyo, 103-8351
    Japan
UsernamePublicRestriction

Register